{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T12:18:48Z","timestamp":1767961128310,"version":"3.49.0"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2004,5,1]],"date-time":"2004-05-01T00:00:00Z","timestamp":1083369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2004,5]]},"DOI":"10.1016\/j.leukres.2003.10.003","type":"journal-article","created":{"date-parts":[[2003,12,4]],"date-time":"2003-12-04T12:02:13Z","timestamp":1070539333000},"page":"53-59","source":"Crossref","is-referenced-by-count":13,"special_numbering":"S1","title":["Imatinib mesylate (STI571) for myeloid malignancies other than CML"],"prefix":"10.1016","volume":"28","author":[{"given":"Geoffrey W","family":"Krystal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2003.10.003_BIB1","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2003.10.003_BIB2","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat. Med."},{"key":"10.1016\/j.leukres.2003.10.003_BIB3","first-page":"100","article-title":"Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative","volume":"56","author":"Buchdunger","year":"1996","journal-title":"Cancer Res."},{"key":"10.1016\/j.leukres.2003.10.003_BIB4","first-page":"139","article-title":"Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors","volume":"295","author":"Buchdunger","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.leukres.2003.10.003_BIB5","doi-asserted-by":"crossref","first-page":"4947","DOI":"10.1182\/blood.V90.12.4947","article-title":"CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins","volume":"90","author":"Carroll","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2003.10.003_BIB6","first-page":"3319","article-title":"The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth","volume":"6","author":"Krystal","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.leukres.2003.10.003_BIB7","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1200\/JCO.20.6.1692","article-title":"Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies","volume":"20","author":"Heinrich","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2003.10.003_BIB8","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1126\/science.289.5486.1938","article-title":"Structural mechanism for STI-571 inhibition of abelson tyrosine kinase","volume":"289","author":"Schindler","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.leukres.2003.10.003_BIB9","doi-asserted-by":"crossref","unstructured":"Tauchi T, Ohyashiki K. Molecular mechanisms of resistance of leukemia to imatinib mesylate. Leukemia Research 2004;28S1:S39\u2013S45.","DOI":"10.1016\/j.leukres.2003.10.007"},{"key":"10.1016\/j.leukres.2003.10.003_BIB10","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa025217","article-title":"A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome","volume":"348","author":"Cools","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2003.10.003_BIB11","doi-asserted-by":"crossref","unstructured":"Pardanani A, Tefferi. Imatinib therapy for hyper-eosinophilic syndrome and eosinophilia\u2013associated myeloproliferative disorders. Leukemia Research 2004;28S1:S47\u2013S52.","DOI":"10.1016\/j.leukres.2003.10.006"},{"key":"10.1016\/j.leukres.2003.10.003_BIB12","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1182\/blood.V99.5.1741","article-title":"The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations","volume":"99","author":"Ma","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2003.10.003_BIB13","first-page":"1115","article-title":"Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant","volume":"1","author":"Frost","year":"2002","journal-title":"Mol Cancer Ther."},{"key":"10.1016\/j.leukres.2003.10.003_BIB14","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0092-8674(03)00190-9","article-title":"Mechanisms of autoinhibition and STI-571\/imatinib resistance revealed by mutagenesis of BCR-ABL","volume":"112","author":"Azam","year":"2003","journal-title":"Cell"},{"key":"10.1016\/j.leukres.2003.10.003_BIB15","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1002\/cncr.10832","article-title":"Characteristics and outcome of patients with Philadelphia chromosome negative, bcr\/abl negative chronic myelogenous leukemia","volume":"95","author":"Onida","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2003.10.003_BIB16","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/(SICI)1098-2264(199711)20:3<299::AID-GCC11>3.0.CO;2-K","article-title":"BCR\/ABL-negative chronic myeloid leukemia with ETV6\/ABL fusion","volume":"20","author":"Andreasson","year":"1997","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.leukres.2003.10.003_BIB17","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1182\/blood.V99.9.3465","article-title":"Transient response to imatinib mesylate (STI571) in a patient with the ETV6-ABL t(912) translocation","volume":"99","author":"O\u2019Brien","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2003.10.003_BIB18","first-page":"329b","article-title":"Imatinib mesylate (Gleevec) induced remission in Philadelphia chromosome-negative\/BCR-ABL negative atypical chronic myelogenous leukemia (CML)","volume":"100","author":"Seftel","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2003.10.003_BIB19","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1126\/science.1079666","article-title":"PDGFRA activating mutations in gastrointestinal stromal tumors","volume":"299","author":"Heinrich","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.leukres.2003.10.003_BIB20","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1172\/JCI116761","article-title":"Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product","volume":"92","author":"Furitsu","year":"1993","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.leukres.2003.10.003_BIB21","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1046\/j.0007-1048.2001.03294.x","article-title":"Class III receptor tyrosine kinases: role in leukaemogenesis","volume":"116","author":"Reilly","year":"2002","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2003.10.003_BIB22","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.V96.3.925","article-title":"Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor","volume":"96","author":"Heinrich","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2003.10.003_BIB23","doi-asserted-by":"crossref","first-page":"10560","DOI":"10.1073\/pnas.92.23.10560","article-title":"Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder","volume":"92","author":"Nagata","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.leukres.2003.10.003_BIB24","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1046\/j.1523-1747.1998.00414.x","article-title":"Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: a possible explanation for divergent clinical behavior","volume":"111","author":"Buttner","year":"1998","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.leukres.2003.10.003_BIB25","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1073\/pnas.96.4.1609","article-title":"Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis","volume":"96","author":"Longley","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.leukres.2003.10.003_BIB26","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/ajh.10322","article-title":"Systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease: analysis of clinicopathologic features and activating c-kit mutations","volume":"73","author":"Pullarkat","year":"2003","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2003.10.003_BIB27","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1046\/j.1365-2141.1997.d01-2042.x","article-title":"A new c-kit mutation in a case of aggressive mast cell disease","volume":"96","author":"Pignon","year":"1997","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2003.10.003_BIB28","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1182\/blood-2001-12-0350","article-title":"Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors","volume":"100","author":"Liao","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2003.10.003_BIB29","doi-asserted-by":"crossref","first-page":"4847","DOI":"10.1074\/jbc.M209321200","article-title":"The Src-selective kinase inhibitor PP1 also inhibits Kit and Bcr-Abl tyrosine kinases","volume":"278","author":"Tatton","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.leukres.2003.10.003_BIB30","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0301-472X(98)00075-7","article-title":"Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit","volume":"27","author":"London","year":"1999","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.leukres.2003.10.003_BIB31","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3109\/10428199409056286","article-title":"Cellular characteristics of acute myeloblastic leukemia associated with t(8; 21)(q22; q22). The Japanese Cooperative Group of Leukemia\/Lymphoma","volume":"13","author":"Kita","year":"1994","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.leukres.2003.10.003_BIB32","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1046\/j.1365-2141.1997.1012917.x","article-title":"Myelomonoblastic leukaemia cells carrying the PEBP2beta\/MYH11 fusion gene are CD34, c-KIT+ immature cells","volume":"97","author":"Osato","year":"1997","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2003.10.003_BIB33","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3109\/10428199809057558","article-title":"Expression of the c-kit (CD117) molecule in normal and malignant hematopoiesis","volume":"30","author":"Escribano","year":"1998","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.leukres.2003.10.003_BIB34","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1182\/blood.V95.2.726","article-title":"C-kit mutations in core binding factor leukemias","volume":"95","author":"Beghini","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2003.10.003_BIB35","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/sj.thj.6200168","article-title":"Amplification of a novel c-Kit activating mutation Asn(822)-Lys in the Kasumi-1 cell line: a t(8;21)-Kit mutant model for acute myeloid leukemia","volume":"3","author":"Beghini","year":"2002","journal-title":"Hematol. J."},{"key":"10.1016\/j.leukres.2003.10.003_BIB36","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1046\/j.1365-2141.1999.01449.x","article-title":"c-kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia","volume":"105","author":"Gari","year":"1999","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2003.10.003_BIB37","first-page":"8118","article-title":"KIT activation is a ubiquitous feature of gastrointestinal stromal tumors","volume":"61","author":"Rubin","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.leukres.2003.10.003_BIB38","doi-asserted-by":"crossref","unstructured":"Meshinchi S, Stirewalt DL, Alonzo TA, Zhang Q, Sweetser DA, Woods WG, et al. Activating mutations of RTK\/ras signal transduction pathway in pediatric acute myeloid leukemia. Blood 2003;Apr 17 [Epub ahead of print].","DOI":"10.1182\/blood-2003-01-0137"},{"key":"10.1016\/j.leukres.2003.10.003_BIB39","first-page":"746a","article-title":"Frequency and clinical significance of c-kit exon 17 mutations in childhood acute myeloid leukemia","volume":"100","author":"Zwaan","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2003.10.003_BIB40","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1182\/blood-2002-05-1469","article-title":"Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, secondary AML","volume":"101","author":"Kindler","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2003.10.003_BIB41","first-page":"266b","article-title":"Remission in a patient with c-kit positive refractory acute myelogenous leukemia after imatinib treatment","volume":"100","author":"Yildirim","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2003.10.003_BIB42","first-page":"264b","article-title":"Imatinib mesylate: antileukemic and myelotoxic effects in patients with AML","volume":"100","author":"Mohr","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2003.10.003_BIB43","first-page":"561a","article-title":"A phase II pilot study of Gleevec\/Glivec (Imatinib Mesylate* STI-571) in patients with c-kit positive acute myeloid leukemia (AML)","volume":"100","author":"Fischer","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2003.10.003_BIB44","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0092-8674(94)90322-0","article-title":"Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(512) chromosomal translocation","volume":"77","author":"Golub","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.leukres.2003.10.003_BIB45","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000046641","article-title":"Myeloproliferative disorders with translocations of chromosome 5q31\u201335: role of the platelet-derived growth factor receptor beta","volume":"107","author":"Steer","year":"2002","journal-title":"Acta Haematol."},{"key":"10.1016\/j.leukres.2003.10.003_BIB46","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJMoa020150","article-title":"Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta","volume":"347","author":"Apperley","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2003.10.003_BIB47","unstructured":"Greipp PT, Dewald GW, Tefferi A. Prevalence and clinical correlates of t(5;12). Blood 2002;100:589a."},{"key":"10.1016\/j.leukres.2003.10.003_BIB48","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(02)08505-7","article-title":"Treatment of hypereosinophilic syndrome with imatinib mesylate","volume":"359","author":"Gleich","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2003.10.003_BIB49","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1056\/NEJM200004273421706","article-title":"Myelofibrosis with myeloid metaplasia","volume":"342","author":"Tefferi","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2003.10.003_BIB50","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1046\/j.1365-2141.2003.04108.x","article-title":"Mutational analysis of class III receptor tyrosine kinases (C-KIT, C-FMS, FLT3) in idiopathic myelofibrosis","volume":"120","author":"Abu-Duhier","year":"2003","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2003.10.003_BIB51","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1182\/blood-2001-12-0154","article-title":"Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia","volume":"99","author":"Tefferi","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2003.10.003_BIB52","unstructured":"Gisslinger H, Gisslinger B, Kees M, Maurer U, Schoder R, Grumbeck E, et al. Imatinib mesylate in chronic idiopathic myelofibrosis, a phase II trial. Blood 2002;100:800a."},{"key":"10.1016\/j.leukres.2003.10.003_BIB53","doi-asserted-by":"crossref","first-page":"4272","DOI":"10.1182\/blood-2001-12-0349","article-title":"Polycythemia vera: myths, mechanisms, and management","volume":"100","author":"Spivak","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2003.10.003_BIB54","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1365-2141.1994.tb03246.x","article-title":"Polycythaemia vera, III, Burst-forming units-erythroid (BFU-E) response to stem cell factor and c-kit receptor expression","volume":"86","author":"Dai","year":"1994","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2003.10.003_BIB55","doi-asserted-by":"crossref","unstructured":"Oehler L, Jaeger E, Eser A, Sillaber C, Gisslinger H, Geissler K. Imatinib mesylate inhibits autonomous erythropoiesis in patients with polycythemia vera in vitro. Blood 2003;May 22 [Epub ahead of print].","DOI":"10.1182\/blood-2003-03-0676"},{"key":"10.1016\/j.leukres.2003.10.003_BIB56","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/00000441-200303000-00007","article-title":"Polycythemia vera responds to imatinib mesylate","volume":"325","author":"Jones","year":"2003","journal-title":"Am. J. Med. Sci."},{"key":"10.1016\/j.leukres.2003.10.003_BIB57","first-page":"44a","article-title":"Imatinib mesylate reduces phlebotomy requirements in polycythemia vera","volume":"100","author":"Silver","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2003.10.003_BIB58","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S0145-2126(00)00161-2","article-title":"Angiogenesis and leukemia","volume":"25","author":"Keyhani","year":"2001","journal-title":"Leuk Res."},{"issue":"Suppl 5","key":"10.1016\/j.leukres.2003.10.003_BIB59","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1634\/theoncologist.6-suppl_5-4","article-title":"Angiogenic growth factors: autocrine and paracrine regulation of survival in hematologic malignancies","volume":"6","author":"Gabrilove","year":"2001","journal-title":"Oncologist"},{"key":"10.1016\/j.leukres.2003.10.003_BIB60","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/nrc905","article-title":"Clinical translation of angiogenesis inhibitors","volume":"2","author":"Kerbel","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.leukres.2003.10.003_BIB61","first-page":"89","article-title":"Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia","volume":"1","author":"Ebos","year":"2002","journal-title":"Mol Cancer Res."},{"key":"10.1016\/j.leukres.2003.10.003_BIB62","doi-asserted-by":"crossref","first-page":"4641","DOI":"10.1182\/blood-2003-02-0481","article-title":"Imatinib normalizes bone marrow vascularity in patients with chronic myeloid leukemia in first chronic phase","volume":"101","author":"Rumpel","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2003.10.003_BIB63","first-page":"5476","article-title":"Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy","volume":"62","author":"Pietras","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.leukres.2003.10.003_BIB64","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1038\/sj.leu.2402555","article-title":"Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec\/Glivec) in chronic myelogenous leukemia: a translational perspective","volume":"16","author":"La Rosee","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2003.10.003_BIB65","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1046\/j.1365-2141.2002.03806.x","article-title":"Combination therapy with imatinib mesylate (STI571): synopsis of in vitro studies","volume":"119","author":"Topaly","year":"2002","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2003.10.003_BIB66","first-page":"3884","article-title":"Effects of signal transduction inhibitor 571 in acute myelogenous leukemia cells","volume":"7","author":"Scappini","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.leukres.2003.10.003_BIB67","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1182\/blood.V97.10.3234","article-title":"Tyrosine kinase inhibitor STI571 potentiates the pharmacologic activity of retinoic acid in acute promyelocytic leukemia cells: effects on the degradation of RARalpha and PML-RARalpha","volume":"97","author":"Gianni\u2019","year":"2001","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521260300328X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521260300328X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,3,27]],"date-time":"2020-03-27T16:02:12Z","timestamp":1585324932000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014521260300328X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,5]]},"references-count":67,"alternative-id":["S014521260300328X"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2003.10.003","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2004,5]]}}}